PATIENTS
CONTACT US

Redefining Bladder Cancer Care:
Non-Invasive, Actionable Insights for Precision Outcomes

Revolutionize NMIBC care with Oncuria—urine-based tests for early detection, monitoring, and predicting response to BCG therapy.
Order Oncuria – Deliver Precise, Patient-Specific Treatment

Bladder Cancer Management Demands Precision, Not Guesswork

Oncuria delivers actionable insights for early detection, personalized BCG therapy decisions, and effective monitoring–because precision saves lives.

Every year, non-muscle-invasive bladder cancer (NMIBC) affects thousands of patients, yet 30–40% fail to respond to BCG therapy¹.

These delays in identifying recurrence or progression can result in unnecessary treatments and worsened outcomes.

What’s the solution? Precision diagnostics that provide actionable insights when they matter most.

With high recurrence rates and limited BCG therapy availability, a lack of precision in care costs both time and patient well-being. Oncuria changes that.

Oncuria Precision Testing:
A Family of Non-Invasive NMIBC Solutions

Oncuria’s urine-based diagnostics empower urologists–like you–with advanced tools to: 

  • Oncuria® Detect: Improves early detection with >90% sensitivity.²
  • Oncuria® Monitor: In patients previously treated for NMIBC, monitor for recurrence while reducing reliance on invasive procedures.
  • Oncuria® Predict: Distinguishes BCG non-responders from BCG responders to avoid unnecessary side effects.

Why Oncuria?

Oncuria’s urine-based diagnostics empower urologists–like you–with advanced tools to: 

  • Data-Driven Accuracy: Validated in clinical trials, Oncuria’s tests achieve a sensitivity of 90%² and a specificity of 86.8%.³
  • Non-Invasive: Replace or supplement invasive procedures like cystoscopy with a simple urine test.
  • Efficient Workflow: Collect, ship, and receive actionable results in days—seamlessly integrated into your practice.

Address Global Challenges with Oncuria’s Precision Solutions

With ongoing BCG global shortages⁴ impacting bladder cancer treatment, Oncuria empowers you to optimize resources while improving patient outcomes confidently:

  • Ensure timely intervention for patients at risk of progression.
  • Minimize patient discomfort with non-invasive testing.
  • Optimize treatment pathways while meeting clinical guidelines.

Three Simple Steps
to Better Outcomes for Your Patients

Implementing the Oncuria testing trio is easy and efficient,
fitting seamlessly into your practice workflow.

Collect:

Collect a urine sample at your clinic.

Ship:

Use our secure shipping process to send the sample to our lab.

Act:

Receive clear, actionable insights to guide your next steps in patient care.

Order Oncuria Today!

The Numbers Speak for Themselves

  • Sensitivity: 93% | Specificity: 86.8%⁵
  • BCG Failure Rate: Up to 40% of patients require alternative treatment strategies.⁶
  • NMIBC recurrence rates: 50–70% within five years⁷

By addressing these challenges, Oncuria helps you deliver better patient outcomes with confidence. 

What You Want to Know About the Oncuria Testing-Trio

The Oncuria family comprises three proprietary tests: 

  • Oncuria® Detect: Designed for the early detection of bladder cancer through biomarker analysis in urine. 
  • Oncuria® Monitor: Tracks progression and treatment response in bladder cancer patients. 
  • Oncuria® Predict: Evaluates the risk of high-grade disease recurrence within 12 to 18 months after initiating BCG treatment. 

Ordering is straightforward:

  • Online Portal: Email [email protected] to request setup credentials. Once established, you can order test kits directly through the portal.
  • Paper Requisition Forms: Email [email protected] to request forms for traditional ordering. 


No prior authorizations are required—just select the appropriate ICD-10 code.

Ready to Redefine the NMIBC Care You Offer?

Phone

+1-833-443-6522 Ext. 1

Email

[email protected]

Personalize bladder cancer treatment and improve outcomes by offering Oncuria.

References:

  1. Correa AF, Theisen K, Ferroni M, Maranchie JK, Hrebinko R, Davies BJ, Gingrich JR. The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer. J Immunol Res. 2015;2015:656918. doi: 10.1155/2015/656918 
  2. Hirasawa, Y., Pagano, I., Chen, R., Sun, Y., Dai, Y., Gupta, A., Tikhonenkov, S., Goodison, S., Rosser, C. J., & Furuya, H. (2021). Diagnostic performance of Oncuria™, a urinalysis test for bladder cancer. Journal of Translational Medicine, 19(1), 141. doi: 10.1186/s12967-021-02796-4 
  3. Heard JR, Mitra AP. Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays. Bladder Cancer. 2024 Mar 12;10(1):71–81. doi: 10.3233/BLC-230096. 
  4. Merck. Facing global shortage, Merck commits to meeting patient demand [press release]. Merck & Co., Inc.; 2024 [accessed December 2, 2024]. 
  5. Heard, JR, & Mitra, AP. (2003). Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays. Journal of Urology, 169(4), 1506-1511. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181788/ 
  6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2.2024. Published February 2024. Accessed December 5, 2024. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf 
  7. Canadian Urological Association. CUA Guidelines on Non-Muscle-Invasive Bladder Cancer. Available at: https://bladdercancercanada.org. Accessed December 5, 2024. 
  8. Oncuria bladder cancer test receives Medicare coverage. DiaCarta website. https://www.diacarta.com/oncuria-bladder-cancer-test-receive-medicare. [Published March 4, 2024]. [accessed December 5, 2024] 

Company

GIAnomics™ Panels

Clinical Updates

Get Started

Contact Us

Speak to one of our representatives today to learn more about our CAP and CLIA-accredited laboratory.

+1 833-443-6522
Facebook-f Instagram Twitter Linkedin Youtube

Copyright © 2025 Genetics Institute of America. All Rights Reserved.